Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Abraxis acquires Shimoda, Platco for $15 million
April 2008
SHARING OPTIONS:

LOS ANGELESóBiotechnology company Abraxis BioScience Inc. has acquired Shimoda Biotech Pty. Ltd. and its subsidiary, Platco Technologies Pty. Ltd., for $15 million.

Located in Plettenberg Bay, South Africa, Shimoda Biotech focuses on the development of new pharmaceutical products by combining successful off-patent molecules with a novel cyclodextrin drug delivery platform, seeking to exploit the faster onset and improved bioavailability characteristics of that platform.

Platco Technologies focuses on the development of novel platinum-based anti-cancer drugs.

Dr. Patrick Soon-Shiong, chairman and CEO of Abraxis, says the companies are valuable acquisitions because they offer a revenue stream from Shimoda's Dyloject, a product pipeline based on a novel cyclodextrin delivery platform and non-steroidal anti-inflammatory drug, as well as access to promising next-generation platinum-based compounds.

"These compounds can expand Abraxis' growing oncology franchise and target global markets in excess of $2 billion," says Dr. Soon-Shiong.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.